Wutah pendapatan taun lumaku: Citius Pharmaceuticals (CTXR)

Logo perusahaan publik Citius Pharmaceuticals Inc. (CTXR)

The YoY sales volume growth trajectory over the rolling period confirms Citius Pharmaceuticals (CTXR) business dependence on the final stages of drug trials. The 0.00 mark serves as a current indicator influenced by FDA delays and capital shortages. Meanwhile, patent protection for infection treatment methods cushions the decline, creating barriers for competitors in the hospital sector.

Citius Pharmaceuticals, Inc. (CTXR): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 17.11.2026

Citius Pharmaceuticals, Inc. - rincian analitis lan metrik utama (CTXR)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:citiuspharma.com
Produk merek citiuspharma.com

Value investing involves searching for early signals of a fundamental business turnaround. This indicator measures revenue dynamics over a rolling year, allowing for the real-time tracking of income recovery rates. For Citius Pharmaceuticals (CTXR), such a metric is critical during the market launch of Mino-Lok and hospital sector drugs. Growth confirms the commercial success of new products. Analyze the last twelve months (LTM) change in commercial revenue to assess the sustainability of the expansion.

Karo sapa Citius Pharmaceuticals saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur Lixte Biotechnology Holdings, Inc.|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur